News & Events

Research and innovation are the cornerstones of AbbVie’s business. The company advances leading-edge science through a dynamic and collaborative approach, enabling them to find better solutions for treating the world’s most challenging diseases. AbbVie focuses on discovering, developing and delivering medicines in therapeutic areas where it has proven expertise and can make an impact. This includes Immunology, Oncology, Neuroscience, Virology and General Medicine.

A Commitment to Data and Information Sharing

There are important health benefits in making clinical trial data and information available to health care providers, researchers, patients and the general public. Thus, AbbVie has adopted national and international principles and standards regarding the sharing and publication of clinical trials data and information. “We are committed to responsible and ethical clinical trial data sharing and believe in its potential to advance scientific knowledge to improve patient care,” said Rob Scott, M.D., chief medical officer and vice president, global pharmaceutical development, AbbVie. “Our collaboration with Vivli supports this commitment and we look forward to a successful partnership and broad uptake of this unique and global platform.”

Find out more about how to access and request AbbVie studies on Vivli.

Vivli presents a conversation between Vivli Executive Director Rebecca Li and Privacy Analytics founder and CEO Dr. Khaled El-Emam. The two discuss the development and features of Vivli, and how global health research benefits from the Vivli-Privacy Analytics partnership.

Use this link to view the free webinar recording:

Increasing Access to a Global Good

About Vivli’s partner, Privacy Analytics:

Privacy Analytics enables business leaders to deploy transformative data strategies, giving them an edge in the hyper-competitive race for innovation and new revenue streams. On the web: www.privacy-analytics.com.

Vivli’s monthly newsletter provides a round-up of activities, resources, member profiles, and other information relevant to the global data sharing and clinical trial research community. You can subscribe at any time to receive via email, or see the most recent issues here.

October 2018 issue

 

The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional efforts in the U.S. and around the world in health and select place-based initiatives. The mission of Vivli aligns directly with this goal.  

“Every day, we are reminded of the urgent need to accelerate medical research. Too many people around the world are suffering from disease and need more effective treatments,” said Stephanie Cuskley, CEO of the Helmsley Charitable Trust, a founding member of Vivli. “Partners like Vivli offer a unique opportunity for research institutions to maximize their impact by sharing data and working together to propel new scientific discoveries forward.”  

Dr. Gina Agiostratidou, Program Director for the Helmsley Charitable Trust’s Type 1 Diabetes (T1D) Program, which aims to advance research, treatments, technologies, and services that improve the life of people with type 1 diabetes, participated as a panelist at the Vivli Platform launch event in July of 2018, demonstrating her organization’s commitment to furthering the reach and benefit of data sharing.  

 

Vivli to use Cochrane vocabulary to power Vivli’s search

Cochrane and Vivli are pleased to announce their partnership aimed at helping health researchers move faster toward new treatments and cures. The first phase of the partnership has been to work together to use the Cochrane ontology to power the Vivli search. Clinical trials included or cited on the Vivli platform are annotated using the Cochrane PICO ontology and vocabulary.

Vivli is a non-profit organization that promotes clinical trial data sharing via a platform designed to serve all elements of the international research community. Cochrane members were invited to try out the Vivli beta website prior to its launch in July.

“This partnership will make it easier to discover and access clinical trial data on the Vivli platform,” said Julie Wood, Vivli’s Director of Strategy and Operations. “Cochrane’s ontology will improve discoverability of data on the Vivli platform and advance quality research. We hope this relationship will continue to grow as we work to make it easier for Cochrane researchers to access clinical trial data. This new partnership will further promote Cochrane’s mission of promoting evidence-informed health decision-making by producing high-quality, relevant, accessible systematic reviews and other synthesized research evidence.”

Chris Mavergames, Head of Informatics & Technology (IT) Services said, “Cochrane is delighted to be working with Vivli to improve access to clinical trial data, and to put our pioneering work in Linked Data into practice for the benefit of the research community worldwide.”

The Vivli platform helps researchers worldwide to discover, share, and analyze data from clinical trials, regardless of who sponsored the research or where the research took place.

Executive Director Rebecca Li joined 2018 Innovative Approaches to Clinical Biomarker Validation conference as a presenter, demonstrating for the attendees the tools Vivli provides to assist in this critical research. The one-day conference, co-hosted by PORTAL, the Harvard Medical School Center for Bioethics, and the Harvard Program in Therapeutic Science, reviewed promising initiatives such as the Vivli platform, and the roles these initiatives can play in driving forward the use of biomarkers in clinical research. Dr. Li introduced Vivli as an innovative platform for sharing and analyzing IPD, including biomarker data.

Announcement and Call for Data Requests: Vivli Pioneers and Global Data Sharing Innovator Awards

Vivli is proud to launch the first of its data analysis challenges to support researchers to explore the studies that are available for searching and requesting on the Vivli platform. More than 3,100 studies are available for searching across numerous disease areas including hypertension, asthma, Crohn’s disease, dementia, and diabetes.

To encourage researchers to derive innovative analysis, drive forward scientific discoveries, and honor the contributions of trial participants, Vivli is launching two awards—the Vivli Pioneer and the Vivli Global Data Sharing Innovator Awards.

What:

The Vivli Pioneer Award will be conferred to the first approved 10 data requests that initiate analysis.  The lead investigators of these data requests will receive $1,000 awards.

The Vivli Global Data Sharing Innovator Award will be conferred to the first 10 data requests that complete and publish their analysis in a peer-reviewed journal. The lead investigator of the data request team (or designated team member) will receive a travel award to enable presenting these results at a future global Vivli Data Sharing meeting.

Winners of the Vivli Pioneer Award are also eligible for the Vivli Global Data Sharing Innovator Award.

Who:

The award is open to all researchers and researcher teams other than those directly employed by for-profit companies.

For questions please contact support@vivli.org. Please use subject line: Vivli Analysis Data Challenge.

How to submit entries:

To be considered for either award, you need to submit a data request on the Vivli platform.

When:

Don’t delay, the first ten data requests that meet either award requirements will be selected. So the sooner you submit a data request the more likely you are to receive the Vivli Pioneer Award. You can then conduct your analysis and, once your results are published in a peer-reviewed journal, be awarded the Vivli Global Data Sharing Innovator Award.

Data Requests should include:

Data Challenge Analysis Requests will follow the Vivli Data Request process. More information, including how to fill out a data request, is available in the Resources section of our site.

To be eligible for the Vivli Pioneer Award and/or the Vivli Global Data Sharing Innovator Award, applicants must request and be approved for more than one study for analysis.

To stay up to date on the latest news about the Vivli Data Analysis Challenge and other news related to data-sharing, please sign up today.

 

First Name
Last Name
Email

How Vivli and Privacy Analytics help data sharing for clinical trials research worldwide

“Sharing clinical trial data is critical in order to inform clinical and regulatory decision making, and honor trial participants who put themselves at risk to advance science.”

– Barbara E. Bierer, M.D., Rebecca Li, Ph.D., Mark Barnes, J.D., LL.M., and Ida Sim, M.D., Ph.D., A GLOBAL, NEUTRAL PLATFORM FOR SHARING TRIAL DATA, The New England Journal of Medicine, article published May 11, 2016, at NEJM.org

Speaking to us from her office in Cambridge, Massachusetts, Dr. Rebecca Li, the Executive Director for Vivli, the non-profit organization that launched its clinical trials data sharing platform in July 2018, shared her perspectives. “As we’ve seen the evolution of clinical trials data sharing, there have been number of initiatives that have blossomed. But one of the gaps in the past, has been the ability to not only share the data, but also to integrate it for cross-platform data sharing. We believe that Vivli brings a unique added value in that regard. It is truly a global, neutral platform.”

Acting as a neutral broker between data contributor, data user and the wider data sharing community, Vivli’s stated objective is to harmonize governance, policy and processes to facilitate data sharing with an independent data repository, in-depth search engine and cloud-based, secure analytics.

Dr. Li provides a human dimension of the Vivli project: “The fact is, that patients who sign on for these clinical trials, want to share their data. When we talk to patients, they are surprised if their data is not being shared. They want to know that their contribution is playing a part in improving research, and advancing health. Therefore, the data needs to be anonymized to respect the patient’s contribution.”

“We occupy a unique position as an umbrella organization that brings together a variety of entities,” Dr. Li observes. Vivli’s members and partners are an esteemed list: The Bill and Melinda Gates Foundation, The Leona M. and Harry B. Helmsley Trust, Harvard University, Duke University, Johns Hopkins University, Pfizer, GSK, Takeda, Wellcome, and Biogen are among those who help make Vivli happen.

As the Vivli platform was designed and built to ensure the security of the anonymized clinical trial participant data that it hosts, enlisting a trusted partner to help data contributors anonymize their data, before sharing it with Vivli, was critical. Privacy Analytics, with its extensive experience in de-identifying highly sensitive personal health information datasets covering a wide bandwidth of sizes and types, was selected to apply its expertise. The pedigree of Privacy Analytics, its founder and Chief Executive Officer, Dr. Khaled El Emam, was a significant factor. “We needed a trusted partner. Dr. El Emam engaged with us during the blueprint stage, and his insights showed us how we could overcome barriers to implementation.”

“There are a number of challenges ahead,” Dr. Li adds. “These include contribution of data, which may exist in unstructured and/or structured form; and being able to use raw data when this is essential to the success of experiments.” Vivli’s impact extends to clinical trials that include patients in a variety of geographic and socioeconomic sectors. “With increased access to patient data, we as a profession, are moving together with our partners. And Vivli is enabling that increased access, for a global good.”

Visit Vivli on the web: https://vivli.org/

Thank you to Privacy Analytics for allowing Vivli to re-publish this piece.

London, U.K.

Executive Director Dr. Rebecca Li spoke at the 2018 DIA Global Clinical Trials Transparency Conference. The three-day event brought together worldwide leaders in data sharing, including representatives from industry, researchers, governmental regulatory agencies and non-profits. Dr. Li introduced the Vivli platform as an innovative means of sharing individual patient data from completed clinical trials, to better support research while also enabling sponsors to meet their own data sharing and transparency mandates.